Casdin Capital, LLC Bei Gene, Ltd. Transaction History

Casdin Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $18.2 Million - $32.4 Million	-150,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $18.6 Million - $29.3 Million	150,000 New	150,000 $28.3 Million
Q2 2019 Aug 13, 2019	SELL	$113.99 - $146.86 $7.98 Million - $10.3 Million	-70,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $5.07 Million - $9.22 Million	52,000 Added 288.89%	70,000 $11.8 Million
Q4 2017 Feb 14, 2018	BUY	$79.6 - $114.73 $1.43 Million - $2.07 Million	18,000	18,000 $1.76 Million

249

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.